EUVIMEDEUVIMED entdecken
Open Access

Design, Synthesis, and In Vitro Evaluation of a PSMA‐Targeted Doxorubicin Conjugate

Sahil Kumar iD, Mrityunjay Tyagi, Riddhi Pal, Birija S Patro, Dibakar Goswami iD

ChemMedChem · 2026

DOI: 10.1002/cmdc.70406 ↗

Kurz gefasst

Fachartikel in der Zeitschrift ChemMedChem, 2026. Verfasst von Sahil Kumar und 4 weiteren Autor:innen. Beteiligte Einrichtung: Bio-Organic Division, Bhabha Atomic Research Centre, Trombay, Mumbai, India. Hauptthemen laut MEDLINE: Doxorubicin, Glutamate Carboxypeptidase II, Drug Design, Antigens, Surface. Die Arbeit nennt 51 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: Department of Atomic Energy, Government of India.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Clinical treatment of prostate cancer, particularly metastatic castration‐resistant prostate cancer (mCRPC), mainly depends on targeting prostate‐specific membrane antigen (PSMA), also known as glutamate carboxypeptidase II (GCPII). Toward this, small molecule–drug conjugates (SMDCs), consisting of a PSMA‐targeting ligand along with a chemotherapeutic, have emerged as an important targeted therapeutic tool. Herein, we have designed 39 ligands with varied targeting heads and linkers and have analyzed their efficacy in silico using molecular docking and molecular dynamics simulation. The best‐docked compound was further synthesized, conjugated with doxorubicin via an acid‐labile imine linkage to yield a novel PSMA–Dox conjugate. This conjugate was evaluated in vitro in PSMA‐positive (LNCaP and C4‐2 cells) and PSMA‐negative (PC3 cells) to establish its selectivity toward PSMA, as well as to ascertain its selective cytotoxicity toward PSMA‐positive cells. Further, cell cycle analysis confirmed the efficacy of the conjugate to induce apoptosis in PSMA‐positive cancer cells. Thus, this study demonstrates a new SMDC which can serve as a template for creating new analogs with enhanced targeting and anticancer efficacy.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

DoxorubicinGlutamate Carboxypeptidase IIDrug DesignAntigens, SurfaceAntineoplastic AgentsHumansApoptosisDrug Screening Assays, AntitumorMolecular Docking SimulationStructure-Activity RelationshipCell Line, TumorCell ProliferationMaleMolecular StructureDose-Response Relationship, DrugMolecular Dynamics Simulation

Stichwörter der Autor:innen

PSMAdoxorubicinpeptideprostate cancertargeted chemotherapy

Substanzen

DoxorubicinGlutamate Carboxypeptidase IIAntigens, SurfaceFOLH1 protein, humanAntineoplastic Agents

Autor:innen und Institutionen

  • Bio-Organic Division, Bhabha Atomic Research Centre, Trombay, Mumbai, India.
  • Homi Bhabha National Institute, Anushaktinagar, Mumbai, India.

ORCID-Profile: Sahil Kumar, Dibakar Goswami

Förderung

  • Department of Atomic Energy, Government of India

Zitieren

APA

Kumar, S., Tyagi, M., Pal, R., Patro, B. S., & Goswami, D. (2026). Design, Synthesis, and In Vitro Evaluation of a PSMA‐Targeted Doxorubicin Conjugate. ChemMedChem. https://doi.org/10.1002/cmdc.70406

Vancouver

Kumar S, Tyagi M, Pal R, Patro BS, Goswami D. Design, Synthesis, and In Vitro Evaluation of a PSMA‐Targeted Doxorubicin Conjugate. ChemMedChem. 2026. doi:10.1002/cmdc.70406

BibTeX
@article{Kumar2026,
  author = {Kumar, Sahil and Tyagi, Mrityunjay and Pal, Riddhi and Patro, Birija S and Goswami, Dibakar},
  title = {Design, Synthesis, and In Vitro Evaluation of a PSMA‐Targeted Doxorubicin Conjugate},
  journal = {ChemMedChem},
  year = {2026},
  doi = {10.1002/cmdc.70406}
}
Kostenlos starten →